enVVeno Medical Corp: One-for-thirty-five reverse stock split effected by filing Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation (effective 2026-01-20).
“To effect the Reverse Stock Split, the Company filed with the Delaware Secretary of State a Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) which became effective as of 12:01 a.m. Eastern Standard Time on Tuesday, January 20, 2026.”
Governance Changes
enVVeno Medical Corp: Amended Section 1.5 of the bylaws to reduce the quorum requirement for stockholder meetings from a majority to 33.33% of voting power (effective 2025-11-17).
“On November 17, 2025, the Board of Directors of enVVeno Medical Corporation (“we,” “us,” “our,” or the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws. The amendment revises Section 1.5 to modify the quorum requirement for meetings of stockholders. As amended, Section 1.5 provides that, except as otherwise required by applicable law, the certificate of incorporation or the bylaws, the presence in person or by proxy of holders of thirty-three and one-third percent in voting power of the outstanding shares entitled to vote at the meeting shall constitute a quorum.”
Listing & Compliance Notices
enVVeno Medical Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“October 7, 2025, enVVeno Medical Corporation (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing”
Listing & Compliance Notices
enVVeno Medical Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“October 7, 2025, enVVeno Medical Corporation (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing”
Jennifer Bright was appointed as Chief Financial Officer at enVVeno Medical Corp.
“On May 19, 2025, the Board of Directors (the “ Board ”) of enVVeno Medical Corporation (the “ Company ”) appointed Jennifer Bright as Chief Financial Officer of the Company.”
Craig Glynn resigned as Chief Financial Officer at enVVeno Medical Corp.
“On May 19, 2025, Craig Glynn resigned as Chief Financial Officer of the Company.”
Auditor Changes
enVVeno Medical Corp engaged CBIZ CPAs P.C. as its auditor.
“On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum LLP ("Marcum") which was engaged as the independent registered public accounting firm of enVVeno Medical Corporation (the "Company"). As a result of this transaction, on April 17, 2025, Marcum resigned as auditors of the Company, and with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs P.C. was engaged as the Company’s new independent registered public accounting firm.”
Auditor Changes
Marcum LLP resigned as auditor of enVVeno Medical Corp.
“On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum LLP ("Marcum") which was engaged as the independent registered public accounting firm of enVVeno Medical Corporation (the "Company"). As a result of this transaction, on April 17, 2025, Marcum resigned as auditors of the Company, and with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs P.C. was engaged as the Company’s new independent registered public accounting firm.”
Shareholder Votes
enVVeno Medical Corp shareholders approved Ratification of the appointment of independent registered public accounting firm at the 2023-12-05 meeting.
“The appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 9,040,316 87,979 20,598 0”
Shareholder Votes
enVVeno Medical Corp shareholders approved Election of Class III directors at the 2023-12-05 meeting.
“Mr. Robert C. Gray was elected as a Class III director to serve for a three-year term that expires at the 2026 annual meeting of stockholders or until his successor is elected and qualified or until his earlier death, incapacity, removal or resignation. The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Votes Mr. Robert C. Gray 5,479,538 887,767 2,781,588”
Material Agreements
enVVeno Medical Corp entered into Registration Rights Agreement with certain institutional investors (effective 2023-10-06).
“In connection with the offering, the Company and the Investors entered into a Registration Rights Agreement dated October 6, 2023 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and Warrant Shares.”
Material Agreements
enVVeno Medical Corp entered into Securities Purchase Agreement with certain institutional investors valued at approximately $28 million (effective 2023-10-06).
“On October 6, 2023, enVVeno Medical Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”) for the purpose of raising approximately $28 million in gross proceeds for the Company.”
Shareholder Votes
enVVeno Medical Corp shareholders approved Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-11-30 meeting.
“Proposal No. 2 – Ratification of the appointment of independent registered public accounting firm The appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 5,445,167 4,108 935 0”
Shareholder Votes
enVVeno Medical Corp shareholders approved Election of Class I directors Mr. Robert A. Berman and Mr. Matthew M. Jenusaitis at the 2022-11-30 meeting.
“Proposal No. 1 – Election of Class I directors Mr. Robert A. Berman and Mr. Matthew M. Jenusaitis were elected as a Class II directors to serve for a three-year term that expires at the 2025 annual meeting of stockholders or until their successors are elected and qualified or until their earlier death, incapacity, removal or resignation. The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Votes Mr. Robert A. Berman 2,378,488 697,978 2,373,744 Mr. Matthew M. Jenusaitis 1,869,004 1,207,462 2,373,744”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.